These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 18507029)
21. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Morales JC; Ruiz-Magaña MJ; Carranza D; Ortiz-Ferrón G; Ruiz-Ruiz C Cancer Lett; 2010 Nov; 297(1):91-100. PubMed ID: 20580868 [TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135 [TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001 [TBL] [Abstract][Full Text] [Related]
24. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Siddiqui IA; Malik A; Adhami VM; Asim M; Hafeez BB; Sarfaraz S; Mukhtar H Oncogene; 2008 Mar; 27(14):2055-63. PubMed ID: 17998943 [TBL] [Abstract][Full Text] [Related]
25. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death. Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257 [TBL] [Abstract][Full Text] [Related]
26. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285 [TBL] [Abstract][Full Text] [Related]
27. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022 [TBL] [Abstract][Full Text] [Related]
28. Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Gahlot S; Khan MA; Rishi L; Majumdar S Biochem Pharmacol; 2010 Dec; 80(11):1650-61. PubMed ID: 20804743 [TBL] [Abstract][Full Text] [Related]
29. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Wagner KW; Punnoose EA; Januario T; Lawrence DA; Pitti RM; Lancaster K; Lee D; von Goetz M; Yee SF; Totpal K; Huw L; Katta V; Cavet G; Hymowitz SG; Amler L; Ashkenazi A Nat Med; 2007 Sep; 13(9):1070-7. PubMed ID: 17767167 [TBL] [Abstract][Full Text] [Related]
30. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. Cillessen SA; Meijer CJ; Ossenkoppele GJ; Castricum KC; Westra AH; Niesten P; Muris JJ; Nijdam HF; van der Hem KG; Flens M; Hooijberg E; Oudejans JJ Br J Haematol; 2006 Aug; 134(3):283-93. PubMed ID: 16848771 [TBL] [Abstract][Full Text] [Related]
31. Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells. Lamy V; Roussi S; Chaabi M; Gossé F; Lobstein A; Raul F Apoptosis; 2008 Oct; 13(10):1232-42. PubMed ID: 18726190 [TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319 [TBL] [Abstract][Full Text] [Related]
34. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385 [TBL] [Abstract][Full Text] [Related]
35. Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Kim MJ; Kim HB; Bae JH; Lee JW; Park SJ; Kim DW; Park SI; Kang CD; Kim SH Biochem Pharmacol; 2009 Sep; 78(6):573-82. PubMed ID: 19464267 [TBL] [Abstract][Full Text] [Related]
36. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681 [TBL] [Abstract][Full Text] [Related]
37. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742 [TBL] [Abstract][Full Text] [Related]
38. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694 [TBL] [Abstract][Full Text] [Related]
39. Targeting death receptors in cancer with Apo2L/TRAIL. Kelley SK; Ashkenazi A Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125 [TBL] [Abstract][Full Text] [Related]
40. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]